Blood test may replace scans for liver cancer treatment monitoring
NCT ID NCT07414433
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether blood tests can predict how well liver cancer responds to a standard treatment called TACE. Researchers will collect blood samples from 60 adults with liver cancer before and after TACE, then compare the results with CT or MRI scans. The goal is to see if blood markers can reliably show early on whether the treatment is working, potentially reducing the need for frequent imaging.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
KBC Bežanijska kosa
Belgrade, Serbia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a 'No-Touch' microwave technique match surgery for liver tumors?
- Can a simple belly press make liver cancer radiation more precise?
- Can a Heat-and-Freeze treatment plus a vaccine outsmart pancreatic cancer?
- Can blood tests reveal how liver and bile duct cancers respond to treatment?
- AI-Powered surveillance may outsmart liver cancer recurrence
- Blood markers may forecast liver cancer treatment success